Continuous administration trial of Phase2 Study of OTS102 in Combination With Gemcitabine in Patients With Unresectable Advanced Biliary Tract Cancer and recurrent Biliary Tract Cancer.

Trial Profile

Continuous administration trial of Phase2 Study of OTS102 in Combination With Gemcitabine in Patients With Unresectable Advanced Biliary Tract Cancer and recurrent Biliary Tract Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2016

At a glance

  • Drugs Elpamotide (Primary) ; Gemcitabine
  • Indications Biliary cancer
  • Focus Therapeutic Use
  • Sponsors OncoTherapy Science
  • Most Recent Events

    • 26 Jul 2012 Planned end date (Dec 2012) added as reported by University Hospital Medical Information Network - Japan record.
    • 16 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 04 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top